دورية أكاديمية
Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report.
| العنوان: | Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report. |
|---|---|
| المؤلفون: | Cai F; Department of Oncology., Zhao Y; Outpatient Department, General Hospital of Northern Theater Command, Shenyang, China., Song S; Department of Oncology., Zhao D; Department of Oncology., Zheng Z; Department of Oncology., Xu L; Department of Oncology. |
| المصدر: | Anti-cancer drugs [Anticancer Drugs] 2024 Sep 01; Vol. 35 (8), pp. 764-768. Date of Electronic Publication: 2024 Jul 16. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Lippincott Williams & Wilkins Original Publication: Oxford, UK : Rapid Communications of Oxford, [1990- |
| مواضيع طبية MeSH: | Aniline Compounds*/therapeutic use , Acrylamides*/therapeutic use , ErbB Receptors*/genetics , Drug Resistance, Neoplasm* , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Crown Ethers*/therapeutic use , Adenocarcinoma of Lung*/drug therapy , Adenocarcinoma of Lung*/genetics , Quinazolines*/therapeutic use , Mutation*, Humans ; Female ; Antineoplastic Agents/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Middle Aged ; Indoles ; Pyrimidines |
| مستخلص: | Based on the FLAURA and AURA III trials, compared to first- and second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), osimertinib provides a longer overall survival benefit for patients with untreated EGFR mutated non-small cell lung cancer. Similar to other EGFR-TKIs, drug resistance is, however, inevitable. The most common mechanism of acquired resistance to first-line osimertinib therapy is the C797S mutation, which accounts for 6% of cases. In view of the current challenges of the development of the next generation of EGFR inhibitors, the mechanism of third-generation targeted drug resistances and targeted strategies are key for further exploration. Our case report discusses a female patient with advanced lung adenocarcinoma carrying the EGFR exon19 E746_A750delinsIP mutation who received osimertinib as first-line therapy and acquired C797S resistance during treatment. The patient was then treated with icotinib for 8 months until the disease progressed. Icotinib may be effective in patients with the EGFR 19del-C797S resistant mutation acquired after osimertinib treatment. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Greig SL. Osimertinib: first global approval. Drugs 2016; 76:263–273. Li Y, Mao T, Wang J, Zheng H, Hu Z, Cao P, et al. Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. Cell Commun Signal 2023; 21:71. Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol 2022; 15:173. Wang S, Song Y, Liu D. EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett 2017; 385:51–54. Arulananda S, Do H, Musafer A, Mitchell P, Dobrovic A, John T. Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer. J Thorac Oncol 2017; 12:1728–1732. Guan YS, He Q, Li MI. activity and clinical application in Chinese patients with lung cancer. Expert Opin Pharmacother 2014; 15:717–728. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376:629–640. Laface C, Maselli FM, Santoro AN, Iaia ML, Ambrogio F, Laterza M, et al. The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies. Pharmaceutics 2023; 15:1604. Kashima K, Kawauchi H, Tanimura H, Tachibana Y, Chiba T, Torizawa T, et al. CH7233163 overcomes osimertinib-resistant EGFR-Del19/T790M/C797S mutation. Mol Cancer Ther 2020; 19:2288–2297. To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, et al. Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer discovery 2019; 9:926–943. Liu Y, Lai M, Li S, Wang Y, Feng F, Zhang T, et al. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Sci 2022; 113:709–720. Conti C, Campbell J, Woessner R, Guo J, Timsit Y, Iliou M, et al. Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC. Cancer Res 2021; 81:1262–1262. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 2019; 121:725–737. Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I, et al. Emerging approaches to overcome acquired drug resistance obstacles to osimertinib in non-small-cell lung cancer. J Med Chem 2022; 65:1008–1046. Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res 2015; 21:3924–3933. Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, et al. Drug sensitivity and allele specificity of first-line osimertinib resistance EGFR mutations. Cancer Res 2020; 80:2017–2030. Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, et al. EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples. J Thorac Oncol 2019; 14:1995–2002. Russo A, Scilla KA, Mehra R, Gittens A, McCusker MG, de Miguel-Perez D, et al. Tracking clonal evolution of EGFR-mutated non-small cell lung cancer through liquid biopsy: management of C797S acquired mutation. Clin Lung Cancer 2023; 24:660–665. Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013; 14:953–961. Meng Y, Li X, Zhang L, Ye M. The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports. Front Oncol 2023; 13:1129629. Ou L, Tang Y, Deng Y, Guo L, He Q, He T, et al. Case report: durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion. Front Oncol 2022; 12:911362. Chen J, Wu X, Wang J. Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation. Front Oncol 2022; 12:898586. Zhang L, Wang L, Wang J, Chen J, Meng Z, Liu Z, et al. Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study. Mol Cancer 2023; 22:124. |
| معلومات مُعتمدة: | 2021JH2/10300091 The Science and Technology Planning project of Liaoning Province |
| المشرفين على المادة: | 3C06JJ0Z2O (osimertinib) 0 (Aniline Compounds) 0 (Acrylamides) EC 2.7.10.1 (ErbB Receptors) 9G6U5L461Q (icotinib) 0 (Crown Ethers) EC 2.7.10.1 (EGFR protein, human) 0 (Quinazolines) 0 (Antineoplastic Agents) 0 (Protein Kinase Inhibitors) 0 (Indoles) 0 (Pyrimidines) |
| تواريخ الأحداث: | Date Created: 20240607 Date Completed: 20240808 Latest Revision: 20240808 |
| رمز التحديث: | 20240808 |
| DOI: | 10.1097/CAD.0000000000001624 |
| PMID: | 38848248 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1473-5741 |
|---|---|
| DOI: | 10.1097/CAD.0000000000001624 |